Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

Background Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology
that has recently found its way into routine practice as an adjunct to tissue biopsy (TB). The …

PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to
detect molecular residual disease (MRD) has the potential to dramatically affect cancer …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …

Simple Summary There is currently a lack of useful tests to detect microscopic residual
disease in patients who have undergone surgery to remove their bowel cancer. This inability …

Introduction Circulating tumor DNA (ctDNA) has been increasingly recognized as a
promising minimally-invasive biomarker that could identify patients with minimal residual …

Background Postoperative minimal residual disease (MRD) detection using circulating-
tumour DNA (ctDNA) requires a highly sensitive analysis platform. We have developed a …

Background Recurrence rates after resection of colorectal cancer liver metastases (CRLM)
are high and correlate with worse survival. Postoperative circulating tumour DNA (ctDNA) is …